To emphasize that gliomas encompass immunologically distinct molecular entities, Table 6 summarizes the immune‐landscape characteristics, dominant biomarkers, and immunotherapeutic strategies specific to each major subtype—IDH-wildtype glioblastoma, IDH-mutant astrocytoma, diffuse midline glioma (DMG), and low-grade gliomas. This evidence concerns the gene IDH1 and glioma.